

2nd Line Relapsed or Metastatic Mucosal HNSCC not NPC

Treatment

No Injectable Lesions

Injectable Lesions

No Prior
Chemo in
R/M Setting

**[ECOG-ACRIN-
EA3202](#)**
[Phase II/III
Chemotherapy +
Cetuximab vs
Chemotherapy +
Bevacizumab vs
Atezolizumab +
Bevacizumab
Following
Progression on
Immune
Checkpoint
Inhibition in
Recurrent/
Metastatic Head
& Neck Cancers](#)

PI: Khan
Sponsor:
ECOG-ACRIN

ENT0100
Phase I
Multicenter Open
Label
First-in-Human
ABBV-CLS-579
Alone and in
Combination in
Locally Advanced
or Metastatic
Tumors

PI: Colevas
Sponsor: AbbVie
Inc.

[ENT0088](#)
[Phase II
Magrolimab
Combination
Therapy in Head
and Neck
Squamous Cell
Carcinoma](#)

Safety Run-in 2 /
Phase 2 Cohort 3
PI: Colevas
Sponsor: Gilead
Sciences, Inc.

Max 4 Prior
Therapies in
R/M Setting

ENT0105
Phase I/II Study
of SRF114 in
Patients With
Advanced Solid
Tumors

PI: Colevas
Sponsor: Surface
Oncology, Inc.

ENT0108
Phase II
Open-Label
Study of
Ozuriftamab
Vedotin (BA3021)
in PD-1/L1
Failure Patients
w/ Recurrent or
Metastatic
Squamous Cell
Carcinoma of the
Head and Neck


PI: Colevas
Sponsor: BioAtla,
Inc.


[ENT0064](#)
[Phase 1b
Ad/PNP-F-
araAMP +
Co-Admin of
Fludarabine
Phosphate in
Recurrent Local
Head and Neck
Cancer](#)

PI: Colevas
Sponsor: PNP
Therapeutics

KEY


 Pending

 Open for Enrollment

 Observational Study

 Optional Path

[Link](#) Trial Posting

 Enrollment on Hold

 Extension Study

 Immunotherapy